Is the price fair?
What AVNS's price assumes
Today's price asks for 33% free cash flow growth a year; over the last three years Avanos Medical, Inc. delivered −51%, the price is ahead of the record.
0.93
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.64%
Free cash flow yield · Medical Devices median 3.9%
- Growth the price implies
- +33%
Growth the price implies · The price pays for +33% free cash flow growth a year for a decade; the business has delivered −51% a year over the last three.
- Price / book
- 0.85
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 0.85
- EV / EBIToperating margin −8.8%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 0.96
- Free cash flow, trailing twelve months
- $7.5M
- Market capitalisation
- $1.17B
- 3-year revenue growth
- +1.5%
- 3-year free cash flow growth
- −51%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Devices
The closest names by size in the same industry